| V |
Report |
Net revenue (FQ3'26, adj/GAAP) |
BEAT |
pred ~$11.50B vs. cons ~$11.36B |
MEDIUM |
| V |
Report |
Non-GAAP diluted EPS (FQ3'26) |
BEAT |
pred ~$3.28 vs. cons ~$3.23 |
MEDIUM |
| V |
Report |
Cross-border volume ex-intra-Europe growth (cst.$, FQ3'26) |
BEAT |
pred ~11.5% vs. cons ~9.5% |
LOW |
| V |
Guide |
Q4 FY2026 net revenue growth (adj., cst.$) |
BETTER |
guide ~12% vs. cons ~11.3% (Q4 FY2026, Jul-Sep 2026) |
MEDIUM |
| V |
Guide |
FY2026 full-year non-GAAP EPS growth (adj.) |
LOWER |
guide ~13% vs. cons ~14.3% (FY2026 full year) |
MEDIUM |
| V |
Guide |
VAS+CMS combined revenue growth normalization commentary |
LOWER |
guide ~18-20% vs. recent run-rate/Street ~25% (FY2026 2H/Q4 outlook) |
LOW |
| V |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| V |
Return |
5-day cumulative residual |
-2.0% (FADE) |
Setup mirrors last quarter's blowout: stock is up ~17% into the print and near highs, so a headline revenue/EPS beat is likely already substantially priced in, and management's own commentary (mid-to-high single-digit EPS growth guide, explicit 'don't extrapolate' language on CMS/VAS one-time items, FIFA lapping into Q4) gives sell-side cover to trim out-quarter (Q4/FY27) estimates even after a Q3 beat. After the April 29 Q2 beat, V popped ~8% on day one but gave back nearly all of it within the next 5 trading days (334.86->318.80, underperforming a rising SPY) as investors digested the guided deceleration and one-time-item caveats; the same implicit-cut dynamic (full-year EPS guide of ~13% sits below Street's ~14.3%, and CMS/VAS growth is being walked back from 24-27% toward high-teens/20%) should again pull estimates and the stock back down over the following week even if the print itself beats. |
MEDIUM |